Viral Vitalism

Source Library

GLP-1 plus therapy can reduce heavy drinking

NIH summary of semaglutide plus therapy trial for heavy drinking in AUD with obesity.

GovernmentGovernment health research
Source type
Government
Access type
Official
Publisher
NIH Research Matters
Date
2026-05-12
Added
2026-06-19
Open original ->Source index

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

91

Government health research

Publisher type
Government research
Bias profile
Low

This source is strongest for safety and clinical outcomes and weaker for consumer context and regulatory status.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->
Regulatory status
66/100
Context Source
Clinical outcomes
90/100
Primary Anchor
Mechanism
90/100
Primary Anchor
Safety
92/100
Primary Anchor
Consumer context
88/100
Strong Support
Trial discovery
89/100
Strong Support

Best used for

  • Research synthesis
  • Public-health context
  • Safety resources

Weak for

  • Primary endpoint extraction when a study is available

Used in Viral Vitalism

Related studies

Semaglutide AUD + ObesityOnce-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity

Related sources

Topic tags

glp-1semaglutidealcohol-use-disorderheavy-drinking

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No selling your information. Unsubscribe anytime.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.